1350323-86-2

Usage

Properties

Synthesized chemical compound
Pyrazole derivative
Contains a methoxy group and a methyl group

Applications in the pharmaceutical industry

Building block in the synthesis of complex organic molecules
Pharmaceutical intermediate

Potential applications

Inhibitor of certain enzymes
Potential anti-cancer agent

Utility in research and chemistry

Valuable tool for researchers and chemists
Used in areas such as drug discovery, medicinal chemistry, and chemical biology

Upstream product

• 52867-35-3 1-methyl-1,2-dihydro-3H-pyrazol-3-one 
• 80-48-8 methyl p-toluene sulfonate 
• 77-78-1 dimethyl sulfate 
• 52867-35-3 1-methyl-3-hydroxy-1H-pyrazole 
• 74-88-4 methyl iodide 

Downstream Products

• 1350323-84-0 3-[(1S)-1-(2-Chloro-3-fluoro-6-methoxyphenyl)ethyl]-5-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1350323-85-1 4-bromo-3-methoxy-1-methyl-1H-pyrazole 

Relevant academic research and scientific papers

FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES

The present invention discloses compounds formula (I): (I) wherein X is CH; The present compounds of formula (I) are dihydroorotate dehydrogenase (DHODH) inhibitors, and are useful for the treatment of inflammatory disorders, autoimmune disorders and cancer, such as e.g. lymphomas, leukemias, carcinomas, and sarcomas. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 60 to 136; examples 1 to 39; tables 1 and 2). An exemplary compound is e.g. : 4-ethyl-1-(7-fluoro-4-isopropyl-2- (2-methoxyphenyl)quinolin-6-yl)-3-(hydroxymethyl)-1H-1,2,4- triazol-5(4H)-one (example 1): (AA)

HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS

The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the prepa

Fused Bicyclic Kinase Inhibitors

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.